Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart et al. Nov 03, 2025 pp. 4505-4505 10.1182/blood-2025-4505

Abstract Background: First-line (1L) therapies for chronic lymphocytic leukemia (CLL) consist of B-cell lymphoma inhibitors (BCL2i) or Bruto...

Evaluating the efficacy of umbilical cord blood transplantation in TP53-mutated AML/MDS: Encouraging survival outcomes

Kepeng Yang, Xiaoyu Zhu, Baolin Tang Nov 03, 2025 pp. 7821-7821 10.1182/blood-2025-7821

Abstract Introduction Subtype of MDS/AML carrying TP53 mutations is reported to have poor outcomes , and it often does n...

The use of MYD88 and IGH PCR in the diagnosis and follow up of Βing-neel syndrome

Ke Xu, June Hyun, Robert Baker et al. Nov 03, 2025 pp. 5736-5736 10.1182/blood-2025-5736

Abstract Background: Bing-Neel syndrome (BNS) is a rare central nervous system involvement of lymphoplasmacytic lymphoma (LPL). The diagnosi...

Rehabilitation needs and clinical associations post CAR T-cell therapy: A retrospective analysis

Kristen Harkins, Dominic Moore, Felicia Cao et al. Nov 03, 2025 pp. 4524-4524 10.1182/blood-2025-4524

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of patients with hematologic malignanci...

Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis

Tejaswini Mariappan, Gurunathan Srinivasan, Haran Srinivasan Saravanan et al. Nov 03, 2025 pp. 7773-7773 10.1182/blood-2025-7773

Abstract Introduction: Graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation...

Poor neutrophil recovery following CD19-targeted CAR-T cell therapy predicts inferior outcomes in adult patients with B-cell lymphoma

Hiroaki Shimizu, Satoshi Koi, Shuhei Kurosawa et al. Nov 03, 2025 pp. 5496-5496 10.1182/blood-2025-5496

Abstract Background: Although CD19-targeted CAR-T cell therapy has improved outcomes for relapsed/refractory B-cell lymphoma, persistent neu...

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

Katherine Tarlock, Danielle Kirkey, Rhonda Ries et al. Nov 03, 2025 pp. 1702-1702 10.1182/blood-2025-1702

Abstract Introduction: Fusions of the NUP98 gene are a recurring feature in acute myeloid leukemia (AML) and occur in approximately 7% of ch...

A case of co-mutation of SF3B1 and BCR::ABL1 demonstrating an MDS-phenotype

Eugene Brailovski, Amirali Vahedi, Véronique Lisi et al. Nov 03, 2025 pp. 6761-6761 10.1182/blood-2025-6761

Abstract INTRODUCTION Co-mutations of BCR::ABL1 and clonal hematopoiesis genes are known to occur in chronic myeloid leu...

Longitudinal and integrated analysis of oral and stool microbiome in allogeneic hematopoietic cell transplantation recipients.

Ronald Siebenaler, E. Anders Kiledal, Marcus Geer et al. Nov 03, 2025 pp. 4225-4225 10.1182/blood-2025-4225

Abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for many benign and malignan...

Comparison of simulated exposure of inotuzumab ozogamicin with and without dose capping in overweight and obese patients with relapsed/refractory acute lymphoblastic leukemia

Nathan Braniff, May Garrett, Jennifer Hibma et al. Nov 03, 2025 pp. 3338-3338 10.1182/blood-2025-3338

Abstract Introduction Inotuzumab ozogamacin (InO) is an antibody drug conjugate (ADC) consisting of a CD22-directed monoclonal antibody linke...

Malignancy as a secondary cause of hemophagocytic lymphohistiocytosis: Outcomes and complications, a national inpatient sample analysis from 2016 to 2020

Santiago Imhoff, Areeba Nayyer, Karishma Narain et al. Nov 03, 2025 pp. 4762-4762 10.1182/blood-2025-4762

Abstract Background Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome driven by uncontrolled activat...

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Jan-Niklas Eckardt, Ishan Srivastava, Chethan Babu et al. Nov 03, 2025 pp. 2558-2558 10.1182/blood-2025-2558

Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous disease. The rise of next-generation-sequencing (NGS) and its incorpora...

Combination of golidocitinib with chidamide for peripheral T-cell lymphoma: Possible mechanisms and therapeutic potential in inhibiting tumor proliferation and modulating the immune microenvironment

Kaiyi Liu, Bing Pan, Li Li Nov 03, 2025 pp. 1778-1778 10.1182/blood-2025-1778

Abstract Background: Peripheral T-cell lymphoma (PTCL) is an aggressive and highly heterogeneous subtype of non-Hodgkin's lymphoma (NHL) der...

Evaluation of payment reimbursement models for teclistamab administration and monitoring in the community hospital setting

Adrian Tsui, Jennifer Forman, Leo Reap et al. Nov 03, 2025 pp. 7943-7943 10.1182/blood-2025-7943

Abstract Background T-cell engaging bispecific antibodies (BsAbs) have emerged as an important class of immunotherapy for the management of...

A novel IL-11/G-CSF mobilization regimen improves delayed platelet engraftment via targeted megakaryocyte progenitor expansion

Xinyu Zuo, Shunrong Sun, Jiexian Ma et al. Nov 03, 2025 pp. 4178-4178 10.1182/blood-2025-4178

Abstract Delayed platelet engraftment (DPE) is a common complication following hematopoietic stem cell transplantation (HSCT) that currently...

Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia

Kaito Harada, Dandan Zhao, Miso Park et al. Nov 03, 2025 pp. 2340-2340 10.1182/blood-2025-2340

Abstract Chimeric antigen receptor (CAR) T cells have shown promise in hematologic malignancies but face major challenges in acute myeloid l...

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Patrick Reagan, Raphael Mwangi, Jean Koff et al. Nov 03, 2025 pp. 6312-6312 10.1182/blood-2025-6312

Abstract Introduction There is currently no standard-of-care for patients (pts) who cannot tolerate full dose anthracycline regimens in fron...

Detection of mutation in cell-free DNA predicts poor outcomes in adult patients with langerhans cell histiocytosis

Long Chang, He Lin, Wei-tong Liu et al. Nov 03, 2025 pp. 2035-2035 10.1182/blood-2025-2035

Abstract Background and aims: Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disease with recurrent MAPK pathway m...

Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia

Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin et al. Nov 03, 2025 pp. 6052-6052 10.1182/blood-2025-6052

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (alloHCT) is the only potentially curative option for high-risk my...

Germline osmr mutation drives familial unicentric castleman disease with osteosclerosis

Miaoyan Zhang, Yan-ting Liu, Yue Dang et al. Nov 03, 2025 pp. 3536-3536 10.1182/blood-2025-3536

Abstract Objective s: Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder characterized by localized lymphadenopathy wi...

The somatic DDX41 hot spot mutation (p.R525H) causes skewed differentiation into plasmacytoid dendritic cells in human iPSC and leukemia models

Junichiro Kida, Maggie Fricker, Emily Stepanchick et al. Nov 03, 2025 pp. 678-678 10.1182/blood-2025-678

Abstract Germline mutations in the RNA-helicase gene DDX41 cause predisposition to myeloid malignancies (MDS/AML) with a penetrance of 50% b...

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Sophie Wollnitza, David Ventura, Marcel Teichert et al. Nov 03, 2025 pp. 5518-5518 10.1182/blood-2025-5518

Abstract Background The use of CD3-CD20-directed bispecific antibodies (BsAb) has significantly improved the outcomes of patients (pts) with...

Dysregulation of fibrinolysis and its relationship with blood cellular indices in acute pulmonary embolism

Mira Nigudkar, Martin Lundy, Fakiha Siddiqui et al. Nov 03, 2025 pp. 1354-1354 10.1182/blood-2025-1354

Abstract Introduction: Pulmonary embolism (PE) is a life-threatening cardiovascular condition characterized by the obstruction of pulmonary...

FerroEVs drive serial propagation of pharmacologically induced ferroptosis in acute leukemia cells

Hiroki Doi, Sumie Fujii, Masaya Hirayama et al. Nov 03, 2025 pp. 2545-2545 10.1182/blood-2025-2545

Abstract Pharmacologically induced cell death not only eliminates target cells but also modulates neighboring cells through bioactive molecu...

First report of high-titer FVIII inhibitor development following AAV-mediated gene therapy in Hemophilia A

Davide Matino, Silvio Ligia, Sarah Kwok et al. Nov 03, 2025 pp. 1297-1297 10.1182/blood-2025-1297

Abstract Over the past decade, adeno-associated virus (AAV) vector–based gene therapy (GT) has emerged as a major advance in hemophilia A (H...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page